Takhzyro is a medicine used to prevent attacks of hereditary angioedema in patients aged 12 years and over.
Patients with angioedema have rapid swelling under the skin in areas such as the face, throat, arms and legs. Attacks of hereditary angioedema can be life threatening when the swelling around the throat presses against the airway.
Takhzyro contains the active substance lanadelumab.
Hereditary angioedema is rare, and Takhzyro was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 9 October 2015.
Takhzyro : EPAR - Medicine overview (PDF/102.78 KB)
First published: 17/12/2018
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Shire Pharmaceuticals Ireland Ltd
|Date of issue of marketing authorisation valid throughout the European Union||
05/03/2020 Takhzyro - EMEA/H/C/004806 - IB/0013
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Other hematological agents
Takhzyro is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.